Cargando…

Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model

OBJECTIVES: Alzheimer's disease (AD) is the most common type of dementia affecting more than 6 million Americans today. Despite the increasing rates of AD there is still no effective cure for this devastating disease. Our lab has shown that elevated plasma branched-chain amino acids (BCAAs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullins, Caitlyn, Mohankumar, Puliyur Seshadri, Reddy, Hemachandra, Shah, Harsh, Shin, Andrew, Siddik, Bakkar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193317/
http://dx.doi.org/10.1093/cdn/nzac047.041
_version_ 1784726429953425408
author Mullins, Caitlyn
Mohankumar, Puliyur Seshadri
Reddy, Hemachandra
Shah, Harsh
Shin, Andrew
Siddik, Bakkar
author_facet Mullins, Caitlyn
Mohankumar, Puliyur Seshadri
Reddy, Hemachandra
Shah, Harsh
Shin, Andrew
Siddik, Bakkar
author_sort Mullins, Caitlyn
collection PubMed
description OBJECTIVES: Alzheimer's disease (AD) is the most common type of dementia affecting more than 6 million Americans today. Despite the increasing rates of AD there is still no effective cure for this devastating disease. Our lab has shown that elevated plasma branched-chain amino acids (BCAAs) and their metabolites are present in both AD patients and mice. Further pilot data revealed that 8 weeks of dietary BCAA restriction in AD mice alleviated AD-related brain pathology and improved cognitive function. Although we observed beneficial effects from the dietary intervention, this approach is practically challenging because BCAAs are found in a wide variety of foods. This prompted us to test the effects of lowering plasma BCAAs in AD mice pharmacologically by BT2, a small molecule that increases BCAA breakdown. METHODS: We used cognitively intact, 2-month-old 5xFAD mice or wildtype (WT) mice to test the effects of BT2 on early AD-related brain pathology. Animals were injected with BT2 or vehicle intraperitoneally (60 mg/kg) for 30 consecutive days. Brain micro punches were taken from the hippocampus for monoamine analysis, and the rest of the hippocampal tissues were used for gene analysis via RT-qPCR. Next, we treated cognitively impaired 4-month-old 5xFAD mice and WT mice with either BT2 (60 mg/kg) or vehicle for 10 consecutive days. We used Golgi-Cox staining to visualize the hippocampus. RESULTS: BT2 treatment in 2-month-old 5xFAD mice restored key neurotransmitters in the hippocampus, the main brain region responsible for learning and memory. BT2 also reduced mRNAs involved in ER stress, inflammation, and Aβ-42 production. Next, we sought to determine if the changes in brain pathology and neurotransmitter status induced by BT2 would result in restored neuronal morphology in the hippocampus of cognitively impaired 5xFAD mice. We observed a clear restoration in dendritic density in the hippocampus of 5xFAD mice treated with BT2 compared to WTs. We did not observe any changes in cognitive function in these mice, possibly due to the short treatment duration. CONCLUSIONS: Our findings suggest that BT2 has therapeutic effects on AD-related pathology in the hippocampus of 5xFAD mice, indicating the potential of BT2 as a novel preventive/treatment strategy for AD. FUNDING SOURCES: NIH R21 AG069140-01
format Online
Article
Text
id pubmed-9193317
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91933172022-06-14 Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model Mullins, Caitlyn Mohankumar, Puliyur Seshadri Reddy, Hemachandra Shah, Harsh Shin, Andrew Siddik, Bakkar Curr Dev Nutr Aging and Chronic Disease OBJECTIVES: Alzheimer's disease (AD) is the most common type of dementia affecting more than 6 million Americans today. Despite the increasing rates of AD there is still no effective cure for this devastating disease. Our lab has shown that elevated plasma branched-chain amino acids (BCAAs) and their metabolites are present in both AD patients and mice. Further pilot data revealed that 8 weeks of dietary BCAA restriction in AD mice alleviated AD-related brain pathology and improved cognitive function. Although we observed beneficial effects from the dietary intervention, this approach is practically challenging because BCAAs are found in a wide variety of foods. This prompted us to test the effects of lowering plasma BCAAs in AD mice pharmacologically by BT2, a small molecule that increases BCAA breakdown. METHODS: We used cognitively intact, 2-month-old 5xFAD mice or wildtype (WT) mice to test the effects of BT2 on early AD-related brain pathology. Animals were injected with BT2 or vehicle intraperitoneally (60 mg/kg) for 30 consecutive days. Brain micro punches were taken from the hippocampus for monoamine analysis, and the rest of the hippocampal tissues were used for gene analysis via RT-qPCR. Next, we treated cognitively impaired 4-month-old 5xFAD mice and WT mice with either BT2 (60 mg/kg) or vehicle for 10 consecutive days. We used Golgi-Cox staining to visualize the hippocampus. RESULTS: BT2 treatment in 2-month-old 5xFAD mice restored key neurotransmitters in the hippocampus, the main brain region responsible for learning and memory. BT2 also reduced mRNAs involved in ER stress, inflammation, and Aβ-42 production. Next, we sought to determine if the changes in brain pathology and neurotransmitter status induced by BT2 would result in restored neuronal morphology in the hippocampus of cognitively impaired 5xFAD mice. We observed a clear restoration in dendritic density in the hippocampus of 5xFAD mice treated with BT2 compared to WTs. We did not observe any changes in cognitive function in these mice, possibly due to the short treatment duration. CONCLUSIONS: Our findings suggest that BT2 has therapeutic effects on AD-related pathology in the hippocampus of 5xFAD mice, indicating the potential of BT2 as a novel preventive/treatment strategy for AD. FUNDING SOURCES: NIH R21 AG069140-01 Oxford University Press 2022-06-14 /pmc/articles/PMC9193317/ http://dx.doi.org/10.1093/cdn/nzac047.041 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the American Society for Nutrition. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Aging and Chronic Disease
Mullins, Caitlyn
Mohankumar, Puliyur Seshadri
Reddy, Hemachandra
Shah, Harsh
Shin, Andrew
Siddik, Bakkar
Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title_full Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title_fullStr Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title_full_unstemmed Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title_short Therapeutic Effects of BT2 in the Hippocampus of Alzheimer's Disease Mouse Model
title_sort therapeutic effects of bt2 in the hippocampus of alzheimer's disease mouse model
topic Aging and Chronic Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9193317/
http://dx.doi.org/10.1093/cdn/nzac047.041
work_keys_str_mv AT mullinscaitlyn therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel
AT mohankumarpuliyurseshadri therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel
AT reddyhemachandra therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel
AT shahharsh therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel
AT shinandrew therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel
AT siddikbakkar therapeuticeffectsofbt2inthehippocampusofalzheimersdiseasemousemodel